L M Aledort

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Optimizing the treatment of haemophilia B: laboratory and clinical perspectives
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Haemophilia 16:1-2. 2010
  2. doi request reprint Why should we care about quality of life in persons with haemophilia?
    L Aledort
    Mount Sinai School of Medicine, Department of Medicine, Division of Hematology Oncology, New York, NY 10029 6574, USA
    Haemophilia 18:e154-7. 2012
  3. doi request reprint Another role for the VW molecule
    L M Aledort
    The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Haemophilia 18:246-7. 2012
  4. doi request reprint Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment
    L M Aledort
    Clinical Research in Hemophilia, The Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 9:423-7. 2011
  5. doi request reprint Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 9:2180-92. 2011
  6. ncbi request reprint Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Haemophilia 14:39-43. 2008
  7. ncbi request reprint Making a therapeutic choice: human versus recombinant fractions - can we do it?
    L M Aledort
    Mt Sinai Medical Center, New York, NY 10029, USA
    Haemophilia 7:1-3. 2001
  8. ncbi request reprint Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    L M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Thromb Haemost 2:1700-8. 2004
  9. ncbi request reprint Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 2:861-2. 2004
  10. ncbi request reprint History of haemophilia
    L M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
    Haemophilia 13:1-2. 2007

Collaborators

Detail Information

Publications29

  1. doi request reprint Optimizing the treatment of haemophilia B: laboratory and clinical perspectives
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Haemophilia 16:1-2. 2010
    ..This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B...
  2. doi request reprint Why should we care about quality of life in persons with haemophilia?
    L Aledort
    Mount Sinai School of Medicine, Department of Medicine, Division of Hematology Oncology, New York, NY 10029 6574, USA
    Haemophilia 18:e154-7. 2012
    ..This article gives a perspective on QOL the importance of QOL measurement in the field of haemophilia and its impact on patient outcome...
  3. doi request reprint Another role for the VW molecule
    L M Aledort
    The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Haemophilia 18:246-7. 2012
    ..My comments on the implication of the vW molecule in down-regulating the immunogenicity of factor VIII...
  4. doi request reprint Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment
    L M Aledort
    Clinical Research in Hemophilia, The Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 9:423-7. 2011
    ..This article reviews similarities and differences in clinical trial guidelines of European and US regulatory agencies and discusses the need for their harmonization to facilitate the assessment of FVIII products...
  5. doi request reprint Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 9:2180-92. 2011
    ..As a result of the infrequency of inhibitors in previously treated patients (PTPs) with hemophilia A and the small size of available clinical studies, the immunogenicity of factor (F)VIII products has been difficult to assess...
  6. ncbi request reprint Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Haemophilia 14:39-43. 2008
    ....
  7. ncbi request reprint Making a therapeutic choice: human versus recombinant fractions - can we do it?
    L M Aledort
    Mt Sinai Medical Center, New York, NY 10029, USA
    Haemophilia 7:1-3. 2001
    ..These issues and others are reviewed in the context of making a therapeutic choice...
  8. ncbi request reprint Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    L M Aledort
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Thromb Haemost 2:1700-8. 2004
    ..Nevertheless, this comprehensive pharmacovigilance assessment does not support superior thrombotic safety of rFVIIa and suggests that thrombotic AE risk may be higher in rFVIIa than FEIBA recipients...
  9. ncbi request reprint Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
    L M Aledort
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Thromb Haemost 2:861-2. 2004
  10. ncbi request reprint History of haemophilia
    L M Aledort
    Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
    Haemophilia 13:1-2. 2007
    ..HD and r products now have similar safety profiles. Several diseases have only HD products for treatment. These products remain important in our treatment armamentarium...
  11. ncbi request reprint Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little
    L M Aledort
    The Mount Sinai Medical Center, New York, NY 10029, USA
    Semin Thromb Hemost 26:189-93. 2000
    ..Data are needed to provide the cost benefit of immune tolerance...
  12. doi request reprint Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII
    L M Aledort
    J Thromb Haemost 9:2325-7. 2011
  13. ncbi request reprint The role of porcine factor VIII in the management of unexpected bleeding episodes
    L M Aledort
    Department of Hemophilia, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1006, New York, NY, USA
    Haemophilia 8:17-9; discussion 28-32. 2002
    ..Case studies will be presented that offer important differential diagnoses. The prevalence and indications for the use of this biological replacement therapy will be discussed...
  14. ncbi request reprint HIV and hemophilia
    L M Aledort
    The Mary Weinfeld Professor of Clinical Research in Hemophilia, Mount Sinai School of Medicine, New York, NY, USA
    J Thromb Haemost 5:607-10. 2007
  15. doi request reprint Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
    Jeffrey Bander
    Mount Sinai School of Medicine, Zena and Michael A Wiener Cardiovascular Institute, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Thromb Haemost 108:86-93. 2012
    ..These findings suggest that a portion of the haematologic benefit of AVR may be due to a postoperative decline in ADAMTS-13 rather than solely to relief of AS as previously thought...
  16. ncbi request reprint Current issues facing coagulationists--meeting report
    S A Brown
    Katharine Dormandy Haemophilia and Haemostasis Unit, Royal Free Hospital, London, UK, and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Haemophilia 12:115-23. 2006
  17. ncbi request reprint AIDS, hepatitis and hemophilia
    L M Aledort
    Mount Sinai School of Medicine, New York, NY, USA
    J Thromb Haemost 2:521. 2004
  18. ncbi request reprint MedWatch: an important instrument for postlicensing surveillance
    L M Aledort
    J Thromb Haemost 4:1637. 2006
  19. ncbi request reprint Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders
    L S Diamondstone
    The Research Kitchen, San Francisco, CA, USA
    Haemophilia 8:660-7. 2002
    ..Better understanding, prevention and control of neutralizing antibodies and hepatitis infections may substantially improve longevity for people with haemophilia...
  20. ncbi request reprint Unresolved issues in prophylaxis
    S A Brown
    Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, London, UK
    Haemophilia 8:817-21. 2002
  21. ncbi request reprint Choice of replacement therapy for hemophilia
    L M Aledort
    J Thromb Haemost 1:596. 2003
  22. ncbi request reprint The economic impact of factor VIII inhibitors in patients with haemophilia
    R L Bohn
    Brigham and Women s Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, MA 02120, USA
    Haemophilia 10:63-8. 2004
    ..Methods to identify high cost inhibitor patients should be developed so that these strategies may be targeted to appropriate candidates...
  23. ncbi request reprint Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C
    D Theodore
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Haemophilia 10:413-21. 2004
    ..This requires close coordination of care between the hepatologist and the haematologist. Indications for liver biopsy should be the same in patients with haemophilia as in other populations...
  24. ncbi request reprint Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done?
    L M Aledort
    J Thromb Haemost 2:1855-6. 2004
  25. ncbi request reprint Economic challenges in haemophilia
    S A Brown
    Katharine Dormandy Haemophilia Centre, Royal Free Hospital, London, UK
    Haemophilia 11:64-72. 2005
  26. ncbi request reprint Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review
    E H Kraut
    Division of Hematology and Oncology, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA
    Haemophilia 13:508-17. 2007
    ....
  27. ncbi request reprint Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura
    L M Aledort
    University Clinics Charite, Berlin, Germany
    Hematology 12:289-95. 2007
    ..This Phase III study examined the efficacy and safety of Rhophylac (CSL Behring AG, Bern, Switzerland), a highly pure, liquid-stable anti-D preparation, in chronic immune thrombocytopenic purpura (ITP)...
  28. ncbi request reprint Prophylaxis in the haemophilia population-optimizing therapy
    M D Carcao
    Division of Haematology Oncology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada
    Haemophilia 13:227-32. 2007
  29. ncbi request reprint Can we prevent inhibitors in mild and moderate factor VIII-deficient patients?
    L M Aledort
    J Thromb Haemost 4:914. 2006